Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PEP-CMV Component B
- Development stage
- Unknown
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Administration
- Intradermal
01
Overview
PEP-CMV Component B is a component of the investigational peptide vaccine known as PEP-CMV, which targets the human cytomegalovirus (CMV) antigen pp65. The full vaccine (PEP-CMV) is designed as an immunotherapy for pediatric and young adult patients with recurrent medulloblastoma, high-grade glioma (HGG), and diffuse intrinsic pontine glioma (DIPG). The main described component in public sources is "Component A," a synthetic long peptide of 26 amino acids derived from CMV pp65, formulated in Montanide ISA 51. There is no detailed public information specifically describing "Component B"—its sequence, function, or whether it represents another peptide or adjuvant within the formulation. It may be an additional synthetic peptide targeting another epitope of CMV or a formulation element distinct from "Component A." As such, its mechanism would be presumed similar to that of other components in the vaccine—eliciting an immune response against CMV antigens present on tumor cells[3][4][5][6].
- Brand names
- PEP-CMV Component B
- Other names
- PEP-CMV Component B
02
Targets
Human Major Histocompatibility Complex class I and II peptide-binding grooves presenting Cytomegalovirus pp65 epitopespp65 (Cytomegalovirus phosphoprotein 65)
Beyond the preview
Go deeper on PEP-CMV Component B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PEP-CMV Component B.